DR. REDDY'S LABORATORIES reported an 86% slump in quarterly profit through March 31 as pricing pressure eroded margins. The result missed analyst estimates by 7.04 billion rupees, marking the second consecutive quarterly decline for the India-based drugmaker. Persistent competition in the U.S. market remains the primary headwind for Dr. Reddy's generic portfolio.

Pricing Pressure Hits the Bottom Line